Improvement in lung function measured by oxygenation levels and markers for disease severity and lung fibrosis

Treatment with sargramostim was safe, well tolerated and generated T-cells targeted at the SARS-CoV-2 virus, indicating a COVID-19 specific immune response

Lexington, MA – February 26, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced top-line results today of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine^® (sargramostim, yeast-derived recombinant human GM-CSF) in hospitalized COVID-19 patients ...

Studies Showed Statistically Significant Improvements in Survival in Subjects Treated with Leukine Starting 48 Hours After Acute, High Dose Radiation Exposure without Need for Blood Transfusions or Other Forms of Intensive Supportive Care 

Leukine Administration Starting 48, 72, 96 and 120 Hours after Lethal Radiation Exposure:

• • Enhanced Recovery of Platelets, Lymphocytes, Neutrophils and Reticulocytes
  • Reduced Frequency, Severity and Duration of Infection, Septicemia and Hemorrhage¹

 Studies Provided the Basis for FDA Approval of Leukine for Treatment of Myelosuppression and Hematopoietic Damage and Dysfunction ...